130 related articles for article (PubMed ID: 9665415)
1. Rapid sequencing of the p53 gene with a new automated DNA sequencer.
Bharaj BS; Angelopoulou K; Diamandis EP
Clin Chem; 1998 Jul; 44(7):1397-403. PubMed ID: 9665415
[TBL] [Abstract][Full Text] [Related]
2. Identification of deletions and insertions in the p53 gene using multiplex PCR and high-resolution fragment analysis: application to breast and ovarian tumors.
Angelopoulou K; Diamandis EP
J Clin Lab Anal; 1998; 12(4):250-6. PubMed ID: 9671178
[TBL] [Abstract][Full Text] [Related]
3. p53 Mutation analysis in breast tumors by a DNA microarray method.
Tennis M; Krishnan S; Bonner M; Ambrosone CB; Vena JE; Moysich K; Swede H; McCann S; Hall P; Shields PG; Freudenheim JL
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):80-5. PubMed ID: 16434591
[TBL] [Abstract][Full Text] [Related]
4. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?
Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961
[TBL] [Abstract][Full Text] [Related]
5. Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas.
Kannan K; Krishnamurthy J; Feng J; Nakajima T; Tsuchida N; Shanmugam G
Int J Oncol; 2000 Nov; 17(5):1031-5. PubMed ID: 11029509
[TBL] [Abstract][Full Text] [Related]
6. Mutations of the p53 gene in human functional adrenal neoplasms.
Lin SR; Lee YJ; Tsai JH
J Clin Endocrinol Metab; 1994 Feb; 78(2):483-91. PubMed ID: 8106638
[TBL] [Abstract][Full Text] [Related]
7. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma.
McIntyre JF; Smith-Sorensen B; Friend SH; Kassell J; Borresen AL; Yan YX; Russo C; Sato J; Barbier N; Miser J
J Clin Oncol; 1994 May; 12(5):925-30. PubMed ID: 8164043
[TBL] [Abstract][Full Text] [Related]
8. High resolution melting for mutation scanning of TP53 exons 5-8.
Krypuy M; Ahmed AA; Etemadmoghadam D; Hyland SJ; ; DeFazio A; Fox SB; Brenton JD; Bowtell DD; Dobrovic A
BMC Cancer; 2007 Aug; 7():168. PubMed ID: 17764544
[TBL] [Abstract][Full Text] [Related]
9. Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay.
Duddy PM; Hanby AM; Barnes DM; Camplejohn RS
J Mol Diagn; 2000 Aug; 2(3):139-44. PubMed ID: 11229518
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas.
Kringen P; Bergamaschi A; Due EU; Wang Y; Tagliabue E; Nesland JM; Nehman A; Tönisson N; Børresen-Dale AL
Biotechniques; 2005 Nov; 39(5):755-61. PubMed ID: 16312222
[TBL] [Abstract][Full Text] [Related]
11. p53 gene mutations and protein accumulation in human ovarian cancer.
Kupryjańczyk J; Thor AD; Beauchamp R; Merritt V; Edgerton SM; Bell DA; Yandell DW
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):4961-5. PubMed ID: 8506342
[TBL] [Abstract][Full Text] [Related]
12. Validation of fluorescent SSCP analysis for sensitive detection of p53 mutations.
Moore L; Godfrey T; Eng C; Smith A; Ho R; Waldman FM
Biotechniques; 2000 May; 28(5):986-92. PubMed ID: 10818706
[TBL] [Abstract][Full Text] [Related]
13. [Greater sensitivity of the PCR-SSCP technique compared with immunohistochemistry for the detection of exon 5 and 6 mutations of gene 53 in breast cancer].
Dueñas González A; Cruz Hernández JJ; Abad Hernández MM; Ramos M; González Sarmiento R
Med Clin (Barc); 1996 May; 106(19):721-4. PubMed ID: 8801382
[TBL] [Abstract][Full Text] [Related]
14. APEX disease gene resequencing: mutations in exon 7 of the p53 tumor suppressor gene.
Shumaker JM; Tollet JJ; Filbin KJ; Montague-Smith MP; Pirrung MC
Bioorg Med Chem; 2001 Sep; 9(9):2269-78. PubMed ID: 11553465
[TBL] [Abstract][Full Text] [Related]
15. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
Sjögren S; Inganäs M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
J Natl Cancer Inst; 1996 Feb; 88(3-4):173-82. PubMed ID: 8632491
[TBL] [Abstract][Full Text] [Related]
16. Mutations of p53 gene in gastric carcinoma in Taiwan.
Wang JY; Lin SR; Hsieh JS; Hsu CH; Huang YS; Huang TJ
Anticancer Res; 2001; 21(1B):513-20. PubMed ID: 11299797
[TBL] [Abstract][Full Text] [Related]
17. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
18. In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high S-phase index.
Merlo GR; Bernardi A; Diella F; Venesio T; Cappa AP; Callahan R; Liscia DS
Int J Cancer; 1993 Jun; 54(4):531-5. PubMed ID: 8514444
[TBL] [Abstract][Full Text] [Related]
19. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
20. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment.
Caleffi M; Teague MW; Jensen RA; Vnencak-Jones CL; Dupont WD; Parl FF
Cancer; 1994 Apr; 73(8):2147-56. PubMed ID: 8156519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
